Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Amortizatization of Intangibles: 2014-2024

Historic Amortizatization of Intangibles for Theravance Biopharma (TBPH) over the last 7 years, with Dec 2024 value amounting to $4.4 million.

  • Theravance Biopharma's Amortizatization of Intangibles fell 11.25% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year decrease of 17.29%. This contributed to the annual value of $4.4 million for FY2024, which is 6.31% up from last year.
  • Theravance Biopharma's Amortizatization of Intangibles amounted to $4.4 million in FY2024, which was up 6.31% from $4.2 million recorded in FY2023.
  • In the past 5 years, Theravance Biopharma's Amortizatization of Intangibles ranged from a high of $4.4 million in FY2024 and a low of $3.3 million during FY2020.
  • Its 3-year average for Amortizatization of Intangibles is $4.2 million, with a median of $4.2 million in 2023.
  • Data for Theravance Biopharma's Amortizatization of Intangibles shows a peak YoY climbed of 13.22% (in 2021) over the last 5 years.
  • Theravance Biopharma's Amortizatization of Intangibles (Yearly) stood at $3.3 million in 2020, then climbed by 13.22% to $3.8 million in 2021, then climbed by 5.36% to $4.0 million in 2022, then grew by 4.09% to $4.2 million in 2023, then rose by 6.31% to $4.4 million in 2024.